{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:08:00Z","timestamp":1790741280192,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009576","name":"Kenneth Rainin Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009576","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK112296"],"award-info":[{"award-number":["R01 DK112296"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.coph.2020.10.002","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T09:58:09Z","timestamp":1604656689000},"page":"90-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Targeting B cells for inflammatory bowel disease treatment: back to the future"],"prefix":"10.1016","volume":"55","author":[{"given":"Tomas","family":"Castro-Dopico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Mehandru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2020.10.002_bib0005","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","article-title":"Inflammatory bowel disease","volume":"28","author":"Kaser","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0010","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.coph.2020.10.002_bib0015","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.coph.2020.10.002_bib0020","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations","volume":"47","author":"Liu","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.coph.2020.10.002_bib0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.coph.2020.10.002_bib0030","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nri2340","article-title":"The genetics and immunopathogenesis of inflammatory bowel disease","volume":"8","author":"Cho","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0035","first-page":"197","article-title":"Comparative mapping of the local distribution of immunoglobulin-containing cells in ulcerative colitis and Crohn\u2019s disease of the colon","volume":"22","author":"Baklien","year":"1975","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0040","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0016-5085(74)80004-1","article-title":"Immunohistochemical characterization of local immunoglobulin formation in ulcerative colitis","volume":"66","author":"Brandtzaeg","year":"1974","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.002_bib0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/gut.38.3.365","article-title":"Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria","volume":"38","author":"Macpherson","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.coph.2020.10.002_bib0050","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0016-5085(87)90552-X","article-title":"Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn\u2019s disease of the colon","volume":"93","author":"Kett","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.002_bib0055","first-page":"197","article-title":"Comparative mapping of the local distribution of immunoglobulin-containing cells in ulcerative colitis and Crohn\u2019s disease of the colon","volume":"22","author":"Baklien","year":"1975","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0060","volume":"vol 2-2","author":"Fuss","year":"2015"},{"key":"10.1016\/j.coph.2020.10.002_bib0065","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/gut.42.6.788","article-title":"Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role","volume":"42","author":"Quinton","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.coph.2020.10.002_bib0070","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/apt.13641","article-title":"Serologic microbial associated markers can predict Crohn\u2019s disease behaviour years before disease diagnosis","volume":"43","author":"Choung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2020.10.002_bib0075","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1572-0241.2007.01577.x","article-title":"IgG antibodies against common gut bacteria are more diagnostic for Crohn\u2019s disease than IgG against mannan or flagellin","volume":"103","author":"Adams","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2020.10.002_sbref0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.08.008","article-title":"Single-cell analysis of Crohn\u2019s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy","author":"Martin","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.coph.2020.10.002_bib0085","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1136\/gutjnl-2012-303063","article-title":"Mucosal CXCR4+ IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through Fc\u03b3R-mediated CD14 macrophage activation","volume":"62","author":"Uo","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.coph.2020.10.002_bib0090","first-page":"1","article-title":"Mucosal IgG in inflammatory bowel disease \u2013 a question of (sub)class?","author":"Castro-Dopico","year":"2019","journal-title":"Gut Microbes"},{"key":"10.1016\/j.coph.2020.10.002_bib0095","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2008.12.046","article-title":"Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn\u2019s disease","volume":"136","author":"Han","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.002_bib0100","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1365-2249.2000.01330.x","article-title":"Autoimmunity in ulcerative colitis (UC): a predominant colonic mucosal B cell response against human tropomyosin isoform 5","volume":"121","author":"Onuma","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0105","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/gut.35.2.224","article-title":"Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease","volume":"35","author":"Hibi","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.coph.2020.10.002_bib0110","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nri2322","article-title":"The regulation of IgA class switching","volume":"8","author":"Cerutti","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0115","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/ni.3213","article-title":"Diversification of memory B cells drives the continuous adaptation of secretory antibodies to gut microbiota","volume":"16","author":"Lindner","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0120","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.immuni.2017.06.013","article-title":"Human secretory IgM emerges from plasma cells clonally related to gut memory B cells and targets highly diverse commensals","volume":"47","author":"Magri","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2020.10.002_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0130","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1136\/gut.2010.225482","article-title":"Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis","volume":"60","author":"Leiper","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.coph.2020.10.002_bib0135","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/00365521.2017.1280530","article-title":"Rituximab-induced Crohn\u2019s disease","volume":"52","author":"Varma","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.coph.2020.10.002_bib0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13730-018-0364-8","article-title":"Crohn\u2019s disease following rituximab treatment in a patient with refractory nephrotic syndrome","volume":"8","author":"Morita","year":"2019","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.coph.2020.10.002_bib0145","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.coph.2020.10.002_bib0150","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.coph.2020.10.002_bib0155","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.002_sbref0160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.13577","article-title":"Efficient long-term depletion of CD20 + B cells by rituximab does not affect gut-resident plasma cells","volume":"1415","author":"Uzzan","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.coph.2020.10.002_bib0165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/tri.12160","article-title":"B-cell regulation and its application to transplantation","volume":"27","author":"Clatworthy","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.coph.2020.10.002_bib0170","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2017-06-789578","article-title":"BAFF and CD4 1 T cells are major survival factors for long-lived splenic plasma cells in a B-cell\u2013depletion context","volume":"131","author":"Thai","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.coph.2020.10.002_bib0175","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2009.07.059","article-title":"An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice","volume":"137","author":"Kobayashi","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.002_sbref0180","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.immuni.2019.02.006","article-title":"Anti-commensal igg Drives Intestinal Inflammation and Type 17 immunity in ulcerative colitis","volume":"50","author":"Castro-Dopico","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2020.10.002_bib0185","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.chom.2015.04.001","article-title":"Humoral immunity in the gut selectively targets phenotypically virulent attaching-and-effacing bacteria for intraluminal elimination","volume":"17","author":"Kamada","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coph.2020.10.002_bib0190","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1083\/jcb.125.6.1407","article-title":"CR3 (Mac-1, alpha M beta 2, CD11b\/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst: requirement for Fc gamma RIII and tyrosine phosphorylation","volume":"125","author":"Zhou","year":"1994","journal-title":"J Cell Biol"},{"key":"10.1016\/j.coph.2020.10.002_bib0195","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4049\/jimmunol.1103703","article-title":"Fc receptor IIb strongly regulates Fc receptor-facilitated T cell activation by dendritic cells","volume":"189","author":"van Montfoort","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0200","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.coph.2020.10.002_bib0205","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.cell.2019.10.027","article-title":"Mucosal profiling of pediatric-onset colitis and IBD Reveals common pathogenics and therapeutic pathways","volume":"179","author":"Huang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.coph.2020.10.002_bib0210","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","article-title":"Intra- and Inter-cellular rewiring of the human colon during ulcerative colitis","volume":"178","author":"Smillie","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.coph.2020.10.002_bib0215","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/j.gastro.2018.05.030","article-title":"Plasma N-glycan signatures are associated with features of inflammatory bowel diseases","volume":"155","author":"Clerc","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.002_sbref0220","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2018.01.002","article-title":"Glycosylation of immunoglobulin G associates with clinical features of inflammatory bowel diseases","volume":"154","author":"\u0160imurina","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.002_bib0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003225","article-title":"Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers","volume":"9","author":"Lauc","year":"2013","journal-title":"PLoS Genet"},{"key":"10.1016\/j.coph.2020.10.002_bib0230","article-title":"Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome","volume":"21","author":"Trbojevi\u0107 Akma\u010di\u0107","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coph.2020.10.002_bib0235","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000166","article-title":"Genetic variants of the MGAT5 gene are functionally implicated in the modulation of T cells glycosylation and plasma IgG glycome composition in ulcerative colitis","volume":"11","author":"Pereira","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.coph.2020.10.002_bib0240","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/j.gastro.2019.08.060","article-title":"Protein glycosylation as a diagnostic and prognostic marker of chronic inflammatory gastrointestinal and liver diseases","volume":"158","author":"Verhelst","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.002_bib0245","doi-asserted-by":"crossref","DOI":"10.1038\/nrgastro.2014.78","article-title":"The role of glycosylation in IBD","volume":"11","author":"Theodoratou","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2020.10.002_bib0250","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's dsease","volume":"350","author":"Sands","year":"2004","journal-title":"New Engl J ed"},{"key":"10.1016\/j.coph.2020.10.002_bib0255","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.002_bib0260","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coph.2020.10.002_bib0265","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.immuni.2016.04.019","article-title":"The TNF receptor superfamily in co-stimulating and co-inhibitory responses","volume":"44","author":"Ward-Kavanagh","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2020.10.002_bib0270","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1073\/pnas.91.15.7007","article-title":"Tumor necrosis factor \u03b1 is an autocrine growth factor for normal human B cells","volume":"91","author":"Boussiotis","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2020.10.002_bib0275","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1572-0241.2002.05689.x","article-title":"Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn\u2019s disease","volume":"97","author":"Esters","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2020.10.002_bib0280","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/ajg.2010.95","article-title":"Disease activity, ANCA, andIL23RGenotype status determine early response to infliximab in patients with ulcerative colitis","volume":"105","author":"J\u00fcrgens","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2020.10.002_bib0285","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.coph.2020.10.002_bib0290","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.coph.2020.10.002_bib0295","first-page":"1","article-title":"T-bet transcription factor promotes antibody-secreting cell differentiation by limiting the inflammatory effects of IFN-\u03b3 on B cells","author":"Stone","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2020.10.002_bib0300","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1073\/pnas.082114899","article-title":"T-bet regulates IgG class switching and pathogenic autoantibody production","volume":"99","author":"Peng","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2020.10.002_bib0305","first-page":"1","article-title":"Regulation of autoantibody activity by the IL-23 \u2013 T H 17 axis determines the onset of autoimmune disease","volume":"18","author":"Pfeifle","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0310","doi-asserted-by":"crossref","DOI":"10.1038\/s41590-019-0415-0","article-title":"Targeting immune cell circuits and trafficking in inflammatory bowel disease","author":"Neurath","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coph.2020.10.002_sbref0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aau4711","article-title":"Anti-\u03b14\u03b27 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals","volume":"10","author":"Uzzan","year":"2018","journal-title":"Science Transl Med"},{"key":"10.1016\/j.coph.2020.10.002_bib0320","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.coph.2020.10.002_bib0325","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10387-7","article-title":"Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases","volume":"10","author":"Rubin","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2020.10.002_bib0330","doi-asserted-by":"crossref","first-page":"S-818","DOI":"10.1016\/S0016-5085(18)32796-3","article-title":"Mo1832 - baseline level of integrin A4B7 on circulating plasmablasts predicts response to vedolizumab in patients with inflammatory bowel disease","volume":"154","author":"Uzzan","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.002_bib0335","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.coph.2020.10.002_bib0340","first-page":"318","article-title":"The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coph.2020.10.002_bib0345","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0350","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1136\/annrheumdis-2014-205615","article-title":"Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro","volume":"73","author":"Wang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2020.10.002_bib0355","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2020.10.002_bib0360","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.immuni.2015.08.007","article-title":"Innate and adaptive humoral responses coat distinct commensal bacteria with immunoglobulin A","volume":"43","author":"Bunker","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2020.10.002_bib0365","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.immuni.2006.05.017","article-title":"Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology","volume":"25","author":"Uhlig","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2020.10.002_bib0370","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1084\/jem.183.2.693","article-title":"Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion","volume":"183","author":"St\u00fcber","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2020.10.002_bib0375","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/intimm\/9.8.1111","article-title":"Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice","volume":"9","author":"Clegg","year":"1997","journal-title":"Int Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0380","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00228-017-2362-8","article-title":"Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases","volume":"74","author":"Albach","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.coph.2020.10.002_bib0385","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4049\/jimmunol.0903888","article-title":"Anti-CD40L Immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice","volume":"185","author":"Robles-Carrillo","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0390","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/annrheumdis-2018-214729","article-title":"Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study","volume":"78","author":"Visvanathan","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2020.10.002_bib0395","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2036.2005.02526.x","article-title":"Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn\u2019s disease","volume":"22","author":"Kasran","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2020.10.002_bib0400","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.coph.2020.10.002_bib0405","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1007\/s10620-016-4317-9","article-title":"B cell-activating factor (BAFF)-targeted B cell therapies in inflammatory bowel diseases","volume":"61","author":"Uzzan","year":"2016","journal-title":"Digest Dis Sci"},{"key":"10.1016\/j.coph.2020.10.002_bib0410","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/S0140-6736(18)30984-X","article-title":"Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial","volume":"391","author":"Banham","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.coph.2020.10.002_bib0415","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.coph.2020.10.002_bib0420","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3899\/jrheum.120886","article-title":"Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"40","author":"Stohl","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coph.2020.10.002_bib0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-03620-2","article-title":"BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus","volume":"9","author":"Shin","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2020.10.002_bib0430","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01228","article-title":"Daratumumab for the treatment of multiple myeloma","volume":"9","author":"Plesner","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0435","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2020.10.002_bib0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2018-024523","article-title":"Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial","volume":"9","author":"Kohler","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.coph.2020.10.002_bib0445","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/MIB.0000000000001116","article-title":"Efficacy and factors associated with treatment response of intravenous immunoglobulin in inpatients with refractory inflammatory bowel diseases","volume":"23","author":"Horton","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coph.2020.10.002_bib0450","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","article-title":"Anti-inflammatory actions of intravenous immunoglobulin","volume":"26","author":"Nimmerjahn","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0455","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2020.10.002_bib0460","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.immuni.2013.11.003","article-title":"Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer","volume":"39","author":"Baker","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2020.10.002_bib0465","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.immuni.2004.05.007","article-title":"Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells","volume":"20","author":"Yoshida","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2020.10.002_bib0470","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20171163","article-title":"Maternal IgG immune complexes induce food allergen-specific tolerance in offspring","volume":"215","author":"Ohsaki","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2020.10.002_bib0475","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1126\/science.aad2571","article-title":"The maternal microbiota drives early postnatal innate immune development","volume":"351","author":"Gomez de Ag\u00fcero","year":"2016","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.coph.2020.10.002_bib0480","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cell.2016.04.055","article-title":"Maternal IgG and IgA antibodies dampen mucosal T helper cell responses in early life","volume":"165","author":"Koch","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.coph.2020.10.002_sbref0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2020.10.002_sbref0490","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coph.2020.10.002_bib0495","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.immuni.2018.08.011","article-title":"IgA responses to microbiota","volume":"49","author":"Bunker","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2020.10.002_bib0500","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.chom.2007.09.013","article-title":"IgA response to symbiotic bacteria as a mediator of gut homeostasis","volume":"2","author":"Peterson","year":"2007","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coph.2020.10.002_bib0505","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.1172747","article-title":"Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism","volume":"325","author":"Slack","year":"2009","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.coph.2020.10.002_bib0510","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22058","article-title":"High-avidity IgA protects the intestine by enchaining growing bacteria","volume":"544","author":"Moor","year":"2017","journal-title":"Nature"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220301004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220301004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:53:39Z","timestamp":1761461619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489220301004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":102,"alternative-id":["S1471489220301004"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2020.10.002","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting B cells for inflammatory bowel disease treatment: back to the future","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2020.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}